ArticleBMC medical imaging2025
Differentiation of non-hypervascular non-functional pancreatic neuroendocrine neoplasms from solid pseudopapillary neoplasms using dual-layer spectral detector CT.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDual-layer spectral detector CT (DLCT) represents an advanced and emerging modality in CT imaging, offering multiparametric images that enhance the quantitative assessment of pancreatic diseases. Non-hypervascular non-functional pancreatic neuroendocrine neoplasms (NF-pNENs) and solid pseudopapillary neoplasms (SPNs) frequently exhibit overlapping clinical and imaging features, complicating their differentiation. This study aimed to investigate the valuable quantitative parameters of DLCT in preoperative differentiation between non-hypervascular NF-pNEN and SPN, as well as to analyze their diagnostic performance.
methodsThis retrospective study included 52 patients with pathologically confirmed non-hypervascular NF-pNENs and SPNs who underwent DLCT examination before surgery between June 2019 and September 2025. To differentiate between non-hypervascular NF-pNENs and SPNs, independent relevant clinical-radiological features and quantitative parameters were identified using the Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis and multivariate logistic regression analysis. The diagnostic performances of independent variables were assessed through receiver operating characteristic curves.
resultsThere were 34 patients with non-hypervascular NF-pNENs (46.7 ± 10.2 years, 19 females) and 18 patients with SPNs (32.8 ± 7.9 years, 14 females). Clinical, radiological features and parameters were evaluated with near-perfect agreements among two radiologists. Age and normalised iodine concentration of lesion in the arterial phase (nICa) were the independent factors for differentiating between non-hypervascular NF-pNENs and SPNs in multivariate logistic regression analysis. The areas under the receiver operating characteristic curves (AUCs) for age, nCTa and nICa in tumour differentiation were 0.855 (95% confidence interval [CI], 0.754-0.956; cutoff, 36 years), 0.797 (95% CI, 0.679-0.916; cutoff, 0.285) and 0.891 (95% CI, 0.806-0.975; cutoff, 0.147), respectively. The combined model (age + nICa) demonstrated the highest performance (AUC = 0.980; 95% CI, 0.952-1.000) when comparing to that of age (P = 0.008), nCTa (P = 0.002) and nICa (P = 0.03), with satisfactory accuracy (92.3%), sensitivity (88.2%) and specificity (100%).
conclusionsThe DLCT parameter nICa combined with age facilitates non-invasive quantitative differentiation between non-hypervascular NF-pNENs and SPNs with satisfactory diagnostic performance. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.